Mariner Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mariner Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-50,000	Closed	-$30K	–	206
2015 Q3	$30K	Sell	50,000 -75,000	-60%	-$10M	0.01%	176
2015 Q2	$504K	Buy	125,000 +75,000	+150%	+$9.29M	0.13%	135
2015 Q1	$288K	Buy	+50,000	New	+$5.3M	0.08%	133
2014 Q4	–	Sell	-15,000	Closed	-$4K	–	244
2014 Q3	$4K	Buy	+15,000	New	+$986K	﹤0.01%	243

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mariner Investment Group's BMRN Position: Q3 2016 in Review

Mariner Investment Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2016, closing a stake of 76,872 shares — an estimated $5.98M sold.

Mariner Investment Group first reported a position in BMRN in Q1 2014 and held it in 8 quarters. The position peaked at $6.32M in Q1 2016. 423 funds tracked by Wall St. Rank hold BMRN as of Q3 2016.

Mariner Investment Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Mariner Investment Group sold 76,872 BioMarin Pharmaceuticals shares in Q3 2016, an estimated $5.98M.
Mariner Investment Group first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 8 quarters.
Mariner Investment Group's BioMarin Pharmaceuticals position peaked at $6.32M in Q1 2016.
423 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2016.

Based on Mariner Investment Group's 13F filing for Q3 2016, filed 3 Nov 2016.